Alopecia

Posts

Global Alopecia Treatment Market

Androgenic Alopecia Market Size

/in /by

Androgenic Alopecia Drug Market Size

Up Market Research offers the latest published report on “Global Global Androgenic Alopecia Drug Market Research Report 2019 Market Research Report 2019” delivering key insights and providing a competitive advantage to clients through a detailed report. The report highly exhibits on current market analysis scenario, upcoming as well as future opportunities, revenue growth, pricing and profitability.

Global Androgenic Alopecia Drug Market Research Report 2019 Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period.

It is a professional and detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along trending innovation and business policies are reviewed in the report. The report contains basic, secondary and advanced information pertaining to the Global Androgenic Alopecia Drug Market Research Report 2019

Market global status and trend, market size, share, growth, trends analysis, segment and forecasts from 2019 – 2026.

The report for Global Androgenic Alopecia Drug Market Research Report 2019 Market analysis & forecast 2019 – 2026 is segmented into Product Segment, Application Segment & Major players.

Region-wise Analysis Global Androgenic Alopecia Drug Market Research Report 2019 Market covers:

• North America
• Europe
• China
• Japan
• India
• Southeast Asia
• Other regions (Central & South America, Middle East & Africa)

The Global Androgenic Alopecia Drug Market Research Report 2019 Market Report can be segmented into Product Types and Applications.

The Report Covers In-Depth Analysis As Follows:

• Chapter 1 Overview of Global Androgenic Alopecia Drug Market Research Report 2019 Market
• Chapter 2 Global Market Status and Forecast by Regions
• Chapter 3 Global Market Status and Forecast by Types
• Chapter 4 Global Market Status and Forecast by Downstream Industry
• Chapter 5 Market Driving Factor Analysis of Global Androgenic Alopecia Drug Market Research Report 2019 Market
• Chapter 6 Global Androgenic Alopecia Drug Market Research Report 2019 Market Competition Status by Major Manufacturers
• Chapter 7 Global Androgenic Alopecia Drug Market Research Report 2019 Market Major Manufacturers Introduction and Market Data
• Chapter 8 Upstream and Downstream Market Analysis of Global Androgenic Alopecia Drug Market Research Report 2019 Market
• Chapter 9 Cost and Gross Margin Analysis of Global Androgenic Alopecia Drug Market Research Report 2019 Market
• Chapter 10 Marketing Status Analysis of Global Androgenic Alopecia Drug Market Research Report 2019 Market
• Chapter 11 Report Conclusion
• Chapter 12 Research Methodology and Reference

“Global Androgenic Alopecia Drug Market Research Report 2019 Market Analysis and Forecast 2019 – 2026” report helps the clients to take business decisions and to understand the strategies of major players in the industry.

The report also calls for market-driven results deriving feasibility studies for client needs. UpMarketResearch ensures qualified and verifiable aspects of market data operating in the real-time scenario. The analytical studies are conducted ensuring client needs with a thorough understanding of market capacities in the real-time scenario.

Global Androgenic Alopecia Drug Market Research Report 2019 Market: Key Stakeholders:

• Manufacturers
• Distributors/Traders/Wholesalers
• Subcomponent Manufacturers
• Industry Association
• Downstream Vendors

In this study, the years considered to estimate the market size of the Global Androgenic Alopecia Drug Market Research Report 2019 Market are as follows:

• History Year: 2013-2018
• Base Year: 2018
• Estimated Year: 2019
• Forecast Year 2019 to 2026

Key Reasons to Purchase:

• To gain insightful analyses of the market and have a comprehensive understanding of the “Global Androgenic Alopecia Drug Market Research Report 2019 Market” and its commercial landscape.
• Learn about the market strategies that are being adopted by your competitors and leading organizations.
• To understand the future outlook and prospects for Global Androgenic Alopecia Drug Market Research Report 2019 Market analysis and forecast 2019 – 2026.

Androgenic Alopecia Drug Market Size

Source

Recent Posts

Global Alopecia Treatment Market

Androgenic Alopecia Market Size

/in /by

Androgenic Alopecia Drug Market Size

Up Market Research offers the latest published report on “Global Global Androgenic Alopecia Drug Market Research Report 2019 Market Research Report 2019” delivering key insights and providing a competitive advantage to clients through a detailed report. The report highly exhibits on current market analysis scenario, upcoming as well as future opportunities, revenue growth, pricing and profitability.

Global Androgenic Alopecia Drug Market Research Report 2019 Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period.

It is a professional and detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along trending innovation and business policies are reviewed in the report. The report contains basic, secondary and advanced information pertaining to the Global Androgenic Alopecia Drug Market Research Report 2019

Market global status and trend, market size, share, growth, trends analysis, segment and forecasts from 2019 – 2026.

The report for Global Androgenic Alopecia Drug Market Research Report 2019 Market analysis & forecast 2019 – 2026 is segmented into Product Segment, Application Segment & Major players.

Region-wise Analysis Global Androgenic Alopecia Drug Market Research Report 2019 Market covers:

• North America
• Europe
• China
• Japan
• India
• Southeast Asia
• Other regions (Central & South America, Middle East & Africa)

The Global Androgenic Alopecia Drug Market Research Report 2019 Market Report can be segmented into Product Types and Applications.

The Report Covers In-Depth Analysis As Follows:

• Chapter 1 Overview of Global Androgenic Alopecia Drug Market Research Report 2019 Market
• Chapter 2 Global Market Status and Forecast by Regions
• Chapter 3 Global Market Status and Forecast by Types
• Chapter 4 Global Market Status and Forecast by Downstream Industry
• Chapter 5 Market Driving Factor Analysis of Global Androgenic Alopecia Drug Market Research Report 2019 Market
• Chapter 6 Global Androgenic Alopecia Drug Market Research Report 2019 Market Competition Status by Major Manufacturers
• Chapter 7 Global Androgenic Alopecia Drug Market Research Report 2019 Market Major Manufacturers Introduction and Market Data
• Chapter 8 Upstream and Downstream Market Analysis of Global Androgenic Alopecia Drug Market Research Report 2019 Market
• Chapter 9 Cost and Gross Margin Analysis of Global Androgenic Alopecia Drug Market Research Report 2019 Market
• Chapter 10 Marketing Status Analysis of Global Androgenic Alopecia Drug Market Research Report 2019 Market
• Chapter 11 Report Conclusion
• Chapter 12 Research Methodology and Reference

“Global Androgenic Alopecia Drug Market Research Report 2019 Market Analysis and Forecast 2019 – 2026” report helps the clients to take business decisions and to understand the strategies of major players in the industry.

The report also calls for market-driven results deriving feasibility studies for client needs. UpMarketResearch ensures qualified and verifiable aspects of market data operating in the real-time scenario. The analytical studies are conducted ensuring client needs with a thorough understanding of market capacities in the real-time scenario.

Global Androgenic Alopecia Drug Market Research Report 2019 Market: Key Stakeholders:

• Manufacturers
• Distributors/Traders/Wholesalers
• Subcomponent Manufacturers
• Industry Association
• Downstream Vendors

In this study, the years considered to estimate the market size of the Global Androgenic Alopecia Drug Market Research Report 2019 Market are as follows:

• History Year: 2013-2018
• Base Year: 2018
• Estimated Year: 2019
• Forecast Year 2019 to 2026

Key Reasons to Purchase:

• To gain insightful analyses of the market and have a comprehensive understanding of the “Global Androgenic Alopecia Drug Market Research Report 2019 Market” and its commercial landscape.
• Learn about the market strategies that are being adopted by your competitors and leading organizations.
• To understand the future outlook and prospects for Global Androgenic Alopecia Drug Market Research Report 2019 Market analysis and forecast 2019 – 2026.

Androgenic Alopecia Drug Market Size

Source

Recent Posts

Global Alopecia Treatment Market

Alopecia Market Scenario Globally

/in /by

Global Statistics Representing Alopecia Market Scenario Globally

Globally, the prevalence of alopecia, such as androgenetic alopecia and alopecia areata, is increasing at a concerning rate. This can be attributed to the rising consumption of unhealthy food, sedentary lifestyle, genetic factors, hormonal imbalance, rising healthcare expenditure, increasing chronic diseases, surging geriatric population, rising disposable incomes, and high focus on aesthetic appearance.

As per the American Hair Loss Association, globally, around 95% of men face hair loss, and over 8, 00,000 people seek treatment for the same. For the record, alopecia is also common in women, and about one-third of women are suffering from androgenetic alopecia across the globe.

Moreover, women suffering from postmenopausal and Polycystic Ovary Syndrome (PCOS) are more likely to develop hair thinning and bald spots adoption of surgical hair transplant and scalp treatments. To attend to the situation, several leading players are actively working to develop novel therapeutic drugs and are heavily investing in R&D activities for the same. For instance, the introduction of fast-acting JAK inhibitors, and PRP treatment is driving the market growth.

Segmental Insights

The global alopecia market is segmented into disease type, end-user, sales channels, and gender.

Alopecia Areata to Witness Significant Growth

By disease type, the alopecia market is further segmented into cicatricial alopecia, alopecia totalis, areata, androgenetic alopecia, Universalis, and among others. The alopecia areata segment is expected to witness significant growth during the forecast period on account of the surging prevalence of a number of diseases, such as diabetes, hyperthyroidism, and Down’s syndrome. Moreover, alopecia totalis and Universalis are the advanced stages of alopecia areata.

The androgenetic alopecia is the fastest-growing segment. It is majorly driven by the launch of pipeline drugs and the increasing prevalence of diseases. It is majorly caused among the individuals associated with a genetic predisposition to hair loss. To attend to the situation, a number of treatment options have been developed by the leading players, including finasteride and minoxidil, licensed topical treatment, and surgical treatment like hair transplant.

Dermatology Clinics to Dominate the Market

By the end-user, the alopecia market is segmented into dermatology, clinics, home care settings, and others.

The dermatology clinics segment is dominating the alopecia market and will continue the same during the forecast period. This can be attributed to the rising number of hair restoration and transplantation surgeries across the globe. The clinic segment is expected to hold a significant share in the market on account of the rising availability of technologically advanced therapies, robust healthcare infrastructure, and growing demand for single session hair restoration procedures across the globe. On 13th May 2019, Bosley and Hair Club announced the launch of BioGraft. The groundbreaking treatment incorporates both surgical and non-surgical hair restoration for rapid transformation and is now available to patients across the globe.

The home care settings segment is majorly driven by the rising number of regulatory approvals for home-use devices, increasing adoption of laser therapy for hair loss treatment, technological advancements, and availability of innovative devices. The laser combs segment is grabbing the highest shares in the home care setting segment as it reduces pain, aids in fast healing, remove the blockage, improves blood circulation, ensures oxygen supply to the scalp, aids in cell replacement, and increases the strength, shine, and elasticity of hair.

Over the Counter Products to Lead the Market

By sales channel, the alopecia market is bifurcated into prescription-based and over the counter (OTC) products. The over the counter products segment is leading the alopecia market. This can be accredited to the growing demand for low-cost treatment and the availability of alternatives. Additionally, a surge in the number of FDA approval for OTC hair loss treatment products is adding fuel to the market growth. For instance, recently, the FDA approved ‘Keranique’ hair regrowth serum and ‘Oscar Blandi hair lift’ serum for instant thickening and strengthening of hair.

By Gender, Alopecia to be More Prevalent in Men than Women

As per the American Hair Loss Association and the U.S. National Library of Medicine, around 50% of men experience hair fall at the age of 50. Moreover, the surge in the geriatric population and high tobacco intake among men is driving the market growth. For the record, some men also experience hair loss in the teens and early twenties due to fluctuating hormones. Whereas, around 40% of the women experience hair loss at the age of 50. Women with menopause are more likely to suffer from hair loss due to a drop in hormone levels. However, alopecia is not permanent in women and can be caused due to stress.

Regional Insights

North America to Dominate the Alopecia Market

North America is dominating the alopecia market on account of increasing advancements in the healthcare infrastructure, availability of novel therapeutics treatment options, rising healthcare expenditure, and high disposable income. As per the U.S. National Library Health Medicine, 1 out of 1000 Americans suffers from alopecia. According to IMS Health, currently, there are around 9,600 dermatologists and about 7,800 dermatology clinics across the U.S. that are arduously working to attend to the situation.

Asia Pacific to be the Fastest Growing Market

Asia Pacific is the fastest growing alopecia market and is expected to grow at a CAGR of 6.9% during the forecast period. This can be attributed to the availability of advanced treatment options and increasing spending power in emerging economies, such as Singapore, India, and China. Moreover, the consumer base in the region prefers traditional alopecia therapy, which includes oil massage and hair masks. In South Korea, China, Japan, and India, the aesthetic drugs are witnessing huge popularity and are anticipated to drive the market growth to some extent.  Other factors driving the market include the rising prevalence of alopecia areata and several skin-related disorders, increasing population, rising incidence of chronic diseases, and changing lifestyle.

South America

South America’s alopecia market is anticipated to reach USD 34.7 million by 2023. Argentina is the fastest growing market in South America on account of the rising geriatric population and sedentary lifestyle. The country is also adopting hair loss treatment and has surpassed a volume of around 52,000 hair loss treatment products in 2017. The region is backed by the presence of leading players that are actively working in the field to sustain in the raging competition. Currently, the players are focusing on developing herbal and natural ingredients to promote hair growth. Furthermore, Brazil is expected to witness significant growth during the forecast period. This can be attributed to the increasing demand for hair care products containing both active and medicinal ingredients.

The Middle East and Africa to Offer Significant Opportunities in the Coming Years

The Middle East and Africa will offer lucrative growth opportunities in the alopecia market during the forecast period owing to increasing technological advancements, rising healthcare expenditures, growing support by the government, and advancement in healthcare facilities.

Competitive Landscape: Market Moving Towards Consolidation

The global alopecia market is highly fragmented in nature, with different market players operating in local regions. Some of the key players are engaging in acquisitions, collaborations, and partnerships to gain a competitive edge. For instance, Johnson & Johnson Consumer, Inc. collaborated with the University of Pennsylvania to design improved preclinical models for the study of human hair growth and androgenetic alopecia. On 6th July 2016,  Alpecin has expanded its footprint in the China market. The alopecia market is consolidated with the presence of Kirkland Signature Vitabiotics, Sun Pharma, Merck & Co., Dr. Reddy’s Laboratories, Cipla, Johnson & Johnson, Alpecin, Phyto Ales Group, and Lifes2good.

Alopecia Market Segmentation

By Disease Type

  • Cicatricial Alopecia
  • Alopecia Totalis
  • Areata
  • Androgenetic Alopecia
  • Universalis
  • Others

By End-User

  • Dermatology
  • Clinics
  • Homecare Settings
  • Others

By Sales Channels

  • Prescription-Based
  • Over the Counter (OTC) Products

By Region

  • Americas
  • Europe
  • Asia–Pacific
  • MEA

Global Statistics Representing Alopecia Market Scenario Globally

Source

Recent Posts

Global Hair Transplant Industry

Hair Transplant Industry Market

/in /by

COVID-19 Outbreak-Global Hair Transplant Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020

The report on Global Hair Transplant Market gives an in-depth analysis of the Hair Transplant market based on aspects that are very important for the market study. Factors like production, market share, revenue rate, regions and key players define a market study start to end. This report gives an overview of the market value in the year 2019 and its growth in the coming years till 2026.

Moreover, the report provides historical information with future forecast over the forecast period. Various important factors such as market trends, revenue growth patterns market shares and demand and supply are included in almost all the market research report for every industry.

Some of the important aspects analyzed in the report include market share, production, key regions, revenue rate as well as key players.

This study covers the following key players

Limmer Hair Transplant Center
Hair Transplants of Florida
Allergan Plc.
LOreal SA
Solta Medical Inc.
Bosley
PhotoMedex Inc.
Restoration Robotics Inc.
ILHT Dubai
The Acibadem Hospitals Group
MEDICAMAT
The Hairline Clinic
Hair Restoration Blackrock HRBR getFUE Hair Clinics Ltd.
Lumenis Inc.
Bernstein Medical
Hair Transplant Center Turkey

Every market research report follows a robust methodology to define its market value. This report on the Hair Transplant market has been very well-drafted to benefit anyone studying it. There is a target set in the market that every marketing strategy has to reach.

In addition, it also covers political and social factors which is likely to affect the growth of the market. It also covers and analysis several segments which are present in the market. Significant development has been recorded by the market of Hair Transplant, in past few years. It is also for it to grow further. Various important factors such as market trends, revenue growth patterns market shares and demand and supply are included in almost all the market research report for every industry.

The report is based on the in-depth view of the Hair Transplant industry on the basis of market growth, market size, development plans and opportunities offered by the global Hair Transplant market. The energetic aspects studied in this report includes SWOT analysis, feasibility and forecast information. For the consumers to gain an in-depth analysis of the global Hair Transplant market and further growth of the market, the report offers significant statistics and information.

Hair Transplant Market segment by Type, the product can be split into

Head Hair Transplant
Eyebrow Transplant
Frontal Hairline Lowering or Reconstruction
Others

Hair Transplant Market segment by Application, split into

Trichology Clinics
Hospitals
Dermatologic Clinics
Others

Hair Transplant market report studies the current state of the market to analyze the future opportunities and risks. Hair Transplant market report provides a 360-degree global market state. Primarily, the report delivers the Hair Transplant introduction, overview, market objectives, market definition, scope, and market size valuation.

On a global level, Hair Transplant industry is segmented on the basis of product type, applications, and regions. It also focuses on market dynamics, Hair Transplant market growth drivers, developing market segments and the market growth curve is offered based on past, present and future market statistics. The industry plans, news, and policies are presented at a global and regional level.

COVID-19 Outbreak-Global Hair Transplant Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020

Source

Recent Posts

Flourish to Combat Female Hair Loss

Flourish to Combat Female Hair Loss

/in /by

Virtue Labs Introduces Flourish to Combat Female Hair Loss

Virtue Labs, makers of the multi-award-winning biotech hair care brand Virtue®, announced today the launch of their new Flourish® product line specifically to target female hair loss and provide thicker, fuller, and healthier hair for all.

While traditionally considered a male problem, half of all women will suffer from hair loss in their lifetime, and 40% by the time they are 40 according to the American Academy of Dermatology.

In fact, there are an estimated 30 million women in the United States suffering from hair loss, and the numbers continue to accelerate. To address this problem, Virtue took a holistic approach in creating this new line by focusing on scalp fertility and, also importantly, on hair fiber survival, with each product in the line powered by their exclusive, groundbreaking keratin protein complex Alpha Keratin 60ku CLINICAL®.

As the scalp is the starting point for hair growth, Virtue Flourish starts there too. Flourish products create a fertile environment for hair to grow by nourishing the microbiome, clearing the follicles, and strengthening the moisture barrier. Because new hair can only survive if it is nurtured and cared for, the Alpha Keratin 60ku CLINICAL nourishes new fragile hair as it emerges, increasing the strength and thickness of each new fiber.

Independent clinical testing showed that after only five uses, Virtue Flourish with Alpha Keratin 60ku CLINICAL increased the thickness of individual hair strands by 22% and reduced hair breakage by 26%, thereby giving new hairs a better chance at survival.

“As a biotech brand born from regenerative medicine, Virtue has always gone where our technology has led us, and that is certainly true with Flourish.

After launching our initial Virtue hair care line, we kept hearing from customers that their hair was growing faster or that they thought they could see new growth. That sent us on a three-year journey of discovery to see what our technology could do if we partnered it with other ingredients specifically to address this crucial problem,” said Melisse Shaban, Founder & CEO of Virtue Labs. “Hair loss is a silent epidemic that women are facing alone. With this launch, we aim to provide truly efficacious products and to shatter the stigma of women’s hair loss with open conversation around this important topic.”

Virtue’s Flourish line features six products that can be purchased individually or within two three-step regimens. The Flourish Nightly Intensive Hair Growth Treatment Regimen ($134) is a three-month regimen for moderate to severe hair thinning and contains Minoxidil, the only single ingredient FDA-approved to help regrow hair in women. The Flourish Nightly Intensive Hair Rejuvenation Treatment Regimen ($134) is a 100% drug-free alternative that features Virtue’s new Density Booster to serve mild to moderate hair thinning and those seeking a more natural approach. The Flourish lineup includes:

  • Flourish Shampoo for Thinning Hair ($42): A gentle, stimulating shampoo that delicately removes scalp buildup, cleanses the hair shaft, and clears debris from follicle openings, creating an environment for healthy growth.
  • Flourish Conditioner for Thinning Hair ($44): A lightweight conditioner that serves as a hair strengthener, hydrator, and detangler all in one. Specifically developed for fine, fragile strands, it nourishes and thickens each hair without weighing it down.
  • Flourish Density Booster ($48): A potent, botanical-based, drug-free nutrient infusion for the scalp, the Density Booster works while you sleep to fuel fatigued follicles and nurture new, fragile hairs so they thrive. For those seeking a more natural solution.
  • Flourish Volumizing Styler ($42): The all-you-need styler for fine, fragile hair, this airy, lightweight formula provides instant body, bounce, and hold, creating the illusion of density even in the thinnest parts.
  • Minoxidil 5% ($28): Used by millions, this is the only single ingredient FDA approved to help regrow hair in women. The nightly application works while you sleep to reactivate the hair follicles and stimulate regrowth.
  • Flourish x Manta Brush ($32): Virtue partnered with U.K. based Manta to offer this uniquely designed brush created specifically for fragile hair. The revolutionary Manta brush bends and molds to the shape of your hand and scalp, creating less tension on each strand. Its flexible bristles glide responsively through the hair, minimizing breakage and restoring a youthful, silky shine.

Virtue Flourish products have been tested through an independent lab on real women under real conditions, and 97% said their scalp feels healthier, 90% said they had more volume and 90% said they saw new growth*.

“Traditionally, hair loss products have been difficult to use, and often harsh on the hair, so women give up before seeing results. Virtue Flourish begins immediately to improve the health and appearance of her existing hair so that she loves the way she looks while she’s growing more,” Shaban said. “We’re excited to present this innovation to women in their search for solutions to their hair loss or thinning.”

Virtue Flourish is available for purchase on virtueflourish.com and will be available in select Bluemercury stores and on Dermstore.com starting in April 2021.

* Consumer perception results after 6 months of Virtue Flourish® Regimen use. Hair growth was seen to be healthier.

+++

About Virtue Labs:

Virtue Labs manufactures and markets innovative, technology-based solutions for the health of hair that provide visible, transformational results. Its proprietary, patented hero ingredient, Alpha Keratin 60ku®, is keratin in its purest, native form – whole, unbroken and fully functional. It is the only fully functional, human-identical keratin protein on the market today, and it is found in each of the company’s Virtue® haircare products. Virtue Labs is based in Raleigh, NC, with a technology manufacturing facility in Winston-Salem, NC. For more information please visit: www.virtuelabs.com.

Virtue Labs Introduces Flourish to Combat Female Hair Loss

Source

Recent Posts

Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies

PRP and Stem cell alopecia

/in /by

U.S. PRP and Stem cell alopecia treatment Market Report Overview

U.S. PRP and Stem cell alopecia treatment market garnered a revenue of USD 129.4 million in the year 2019 globally and is anticipated to reach USD 189.2 million by 2027, growing at a compound annual growth (CAGR) of 4.9% over the forecast period.

The market has been observed to be growing at a steady growth rate over the last three years, however, with the impact of the COVID-19 pandemic globally, the business conditions are expected to change. The market size may reduce significantly or increase with a spike depending on how the value chain has been affected in the entire process.

Players that are operational in the market for a longer period of time are anticipated to absorb the sudden changes, losses and increased operational costs better than those who have recently entered the market.

The report focuses on numerous factors that are anticipated to impact the market growth directly and indirectly. The report categorically analyses the growth patterns of different segments based on multiple derivation models.

Both the qualitative and quantitative aspects have been covered under the report. The U.S. PRP & Stem cell alopecia treatment market report includes market size, drivers, restraints, opportunities and trends that will help you understand the market dynamics in detail.

Moreover, the report will include market estimates & forecasts in terms of revenue for the overall market along with the segments mentioned in the study. The report focuses on providing a holistic view of the entire market scenario from multiple unmatched detailed analysis mentioned in the report.

What to expect from the report?

  • U.S. PRP and Stem cell alopecia treatment Total Available Market (TAM)Size
  • U.S. PRP and Stem cell alopecia treatment Serviceable Available Market (SAM) Size
  • Business Implications of COVID-19 on the Overall Market
  • Market Share/ Revenue Share (%) of Top Market Players in Total Market Size (2019)
  • Market Size & Forecast (2016-2027) At Country & Regional Level, By Segments
  • Overview & Analysis of Key Players Operating in the Market

Key Highlights:

COVID-19 – Impact of COVID-19 on overall business scenario

U.S. PRP and Stem cell alopecia treatment Market Revenue 2020

Global market revenue in 2020 will be derived taking into various micro & macro-level factors; along with the COVID-19 pandemic

Competitive Analysis Company Market Share Analysis, 2019 (%)

Supply Chain Analysis – Analysis pertaining to several participants of the supply chain such as raw material suppliers, distributors, & OEMs along with others will be highlighted in the study

Data Source Primary & Secondary Research, Internal DataBase & Company Annual Reports

Regions Included North America,

Countries Included U.S., Canada,

U.S. PRP and Stem cell alopecia treatment Market Report Overview

Source

Recent Posts

Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies

Stem Cell and Platelet Rich Plasma Alopecia Therapies

/in /by

COVID-19 Impact on Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size, Status and Forecast 2020-2026t

This report focuses on the global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study

Orange County Hair Restoration Center
Hair Sciences Center of Colorado
Anderson Center for Hair
Evolution Hair Loss Institute
Savola Aesthetic Dermatology Center
Virginia Surgical Center
Hair Transplant Institute of Miami
Colorado Surgical Center & Hair Institute

Market segment by Type, the product can be split into

Platelet Rich Plasma Injections
Stem Cell Therapy
Market segment by Application, split into
Dermatology Clinics
Hospitals

Market segment by Regions/Countries, this report covers

North America
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:

To analyze global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies status, future forecast, growth opportunity, key market and key players.
To present the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies are as follows:

History Year: 2015-2019
Base Year: 2019
Estimated Year: 2020
Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Summary:

Get the latest Market Research Reports on COVID-19 Impact on Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies. Industry analysis & Market Report on COVID-19 Impact on Global Stem

Cell and Platelet Rich Plasma (PRP) Alopecia Therapies is a syndicated market report, published as COVID-19 Impact on Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size,

Status and Forecast 2020-2026. It is a complete Research Study and Industry Analysis of COVID-19 Impact on Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market, to understand,

Market Demand, Growth, trends analysis and Factor Influencing market.

COVID-19 Impact on Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size, Status and Forecast 2020-2026

Source

Recent Posts

Hair Regrowth in Phase 3 Alopecia Areata

Hair Regrowth in Phase 3 Alopecia Areata

/in /by

Baricitinib is First JAK-Inhibitor to Demonstrate Hair Regrowth in Phase 3 Alopecia Areata (AA) Trial

Eli Lilly and Company announced today top-line results from BRAVE-AA2, a Phase 3 study evaluating the efficacy and safety of once-daily baricitinib 2-mg and 4-mg in adults with severe alopecia areata (AA).

Both doses of baricitinib met the primary efficacy endpoint at Week 36, demonstrating a statistically significant improvement in scalp hair regrowth compared to those randomized to placebo. AA is an autoimmune disease that causes patchy hair loss on the scalp, face and sometimes on other areas of the body that can progress.

Baricitinib has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for the treatment of AA. This classification aims to expedite the development and review of drugs that are intended to treat a serious condition when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over already available therapies on a clinically significant endpoint(s). There are currently no FDA-approved treatments for AA.

“These positive results are very promising and suggest that baricitinib has the potential to address the urgent needs of people living with alopecia areata,” said Brett King, M.D., Ph.D., associate professor of Dermatology at Yale School of Medicine. “This level of high-quality research is needed to advance our understanding and the treatment of this frequently devastating disease.”

This multicenter, randomized, double-blind, placebo-controlled study included 546 adults with a Severity of Alopecia Tool (SALT) score ≥ 50 (i.e., who had ≥50% scalp hair loss) and a current episode of severe AA lasting at least six months but no more than eight years. The study included a diverse patient population from Argentina, Australia, Brazil, China, Israel, Japan, South Korea, Taiwan and the U.S.

Safety outcomes of baricitinib in BRAVE-AA2 were consistent with its established safety profile in patients with rheumatoid arthritis (RA) and atopic dermatitis (AD). No deaths, major adverse cardiovascular events (MACE) or venous thromboembolic events (VTEs) were reported in the study.

BRAVE-AA2 is the first Phase 3 study with positive results in patients with AA. Data from an additional Phase 3 study of baricitinib in AA will be available in the first half of this year. Detailed results from the BRAVE program will be presented at an upcoming medical conference and published in a peer-reviewed journal later this year. AA is the second potential treatment indication in dermatology for baricitinib after AD.

“For patients who suffer from alopecia areata, it is not a cosmetic condition, it is a devastating autoimmune disease that can have significant psychological effects. They lose much more than just hair,” said Lotus Mallbris, M.D., Ph.D., vice president of immunology development at Lilly. “We are looking forward to sharing the totality of data from the overall clinical development program for baricitinib as a potential first-in-disease treatment for alopecia areata.”

“Significant unmet need exists in the treatment of alopecia areata,” said Abby Ellison, research director at the National Alopecia Areata Foundation (NAAF). “We appreciate Lilly’s important work in this area and are excited that these data could bring us closer to a potential new treatment option for patients.”

Baricitinib is an oral JAK inhibitor discovered by Incyte and licensed to Lilly. It is approved and commercially available as OLUMIANT in the U.S. and more than 70 countries as a treatment for adults with moderate to severe active RA and in the European Union and Japan for the treatment of adult patients with moderate to severe AD who are candidates for systemic therapy. Baricitinib is also being investigated in systematic lupus erythematosus (SLE), juvenile idiopathic arthritis (JIA) and COVID-19.

Baricitinib is First JAK-Inhibitor to Demonstrate Hair Regrowth in Phase 3 Alopecia Areata (AA) Trial

Source

Recent Posts

Global Alopecia Treatment Market

Speaker discusses use of JAK inhibitors in alopecia

/in /by

Speaker discusses use of JAK inhibitors in alopecia

A speaker at South Beach Symposium Medical Dermatology Summit discussed the JAK inhibitors that are currently on the market and their applications in treating alopecia areata.

Antonella Tosti, MD, said that JAK inhibitors “are probably the future of treatment for alopecia areata.”

Of the three main JAK inhibitors used for alopecia areata — ruxolitinib, baricitinib and tofacitinib — tofacitinib “has been most studied,” Tosti said. The standard dose of tofacitinib is 5 mg twice daily.

Patients usually regrow hair about 3 months after beginning treatment, and even though some patients may take longer, they should “persist and continue the treatment,” she said.

About 70% of patients respond to tofacitinib, although it is typically less effective in long-standing alopecia totalis or alopecia universalis. However, the oral formulation is more effective than the topical formulation, Tosti said.

Large clinical trials for ruxolitinib and baricitinib are ongoing, according to Tosti. In the literature cited during the presentation, ruxolitinib doses were 10 mg twice daily and 10 mg every other day. She also said “usually ruxolitinib causes visible regrowth earlier than tofacitinib.”

There is not yet data on long-term side effects, but patients commonly experience upper respiratory infections, headache and weight gain. Given the potential danger of upper respiratory infections during the era of COVID-19, Tosti has advised her patients to discontinue treatment if they develop COVID-19 symptoms. Other side effects, such as severe infection, have been reported among patients taking a JAK inhibitor for another indication.

Tosti said there are several JAK inhibitor compounds in the phase 2 or 3 stage of development.

Speaker discusses use of JAK inhibitors in alopecia

Source

Recent Posts

Global Alopecia Treatment Market

Study Results for the Treatment of Androgenic Alopecia

/in /by

Histogen Announces Week 26 HST-001 Study Results for the Treatment of Androgenic Alopecia in Men

Histogen today announced week 26 results from its Phase 1b/2a clinical trial of HST-001 in male patients with androgenic alopecia. At the week 26 timepoint, patients treated with HST-001 demonstrated a statistically significant change from baseline in total hairs (terminal and vellus) in the target area (TAHC) in the vertex as measured by Canfield’s Hairmetrix macrophotography system.

HST-001 was also shown to be safe and well-tolerated at week 26 as compared to placebo with no reports of serious adverse events. Similar to the week 18 primary endpoint results we reported in December of 2020, HST-001 did not achieve statistical significance at week 26 when compared to placebo.

“The recently completed study demonstrated that HST-001 was safe, well-tolerated, and exhibited signals of efficacy. This data will inform future development, and I look forward to working with Histogen and our other expert advisors as we plan and execute the next study in men with androgenetic alopecia,” said Dr Stacy Smith, M.D., founder of the California Dermatology and Clinical Research Institution and principal investigator for the HST-001 trial.

“We are encouraged that these results demonstrated that patients treated with HST-001 grow both terminal and vellus hairs in men with androgenic alopecia,” said Richard W. Pascoe, Histogen’s President and CEO. “Moreover, 84% of the subjects who received HST-001 responded to treatment over the 26-week period and the study drug was found to be safe and well-tolerated across all subjects.

With this data in hand, we have begun planning for a more substantive clinical trial in men with androgenic alopecia with the goal of determining the best clinical pathway for future registration trials. We anticipate the trial will commence in the second half of 2021.”

About the HST-001 Phase 1a/2b Study
This 2:1 randomized, blinded, the placebo-controlled, single-site study enrolled 36 male patients with androgenic alopecia with mild to moderate hair loss on a Norwood-Hamilton (N-H) Scale (3V, 4, 5), with a total of 30 evaluable patients at week 26.

It was designed to assess the safety and tolerability of HST-001, as well as indicators of efficacy at weeks 18 and 26. The primary study endpoint is an absolute change from baseline versus week 18 in total hairs (terminal and vellus) in the (TAHC) of the vertex as measured by Canfield’s Hairmetrix macrophotography system.

Secondary endpoints include absolute change from baseline in total hairs (terminal and vellus) new terminal and vellus hair count, hair thickness density and per cent change from baseline in TAHC, terminal and vellus hair counts in the vertex and right temporal regions at weeks 18 and 26, all as measured by Canfield’s Hairmetrix macrophotography system. At each treatment time point (Weeks 0, 6 and 12), patients received a total of 20 injections, 10 in the vertex scalp region and 5 in each temporal region for a total dose of 2mL.

About HST-001
HST-001, or Hair Stimulating Complex (HSC), is intended to be a physician-administered therapeutic for hair loss. HSC is anticipated to be a relatively safe, minimally invasive treatment that promotes new hair growth where existing treatments only reduce hair loss. HSC is manufactured to enrich for growth factors including KGF, VEGF and follistatin, which are involved in signaling stem cells in the body and have been shown to be important in hair formation and the stimulation of resting hair follicles.

About Histogen
Histogen Inc. is a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function.

Histogen’s innovative technology platform utilizes cell conditioned media and extracellular matrix materials produced by hypoxia-induced multipotent cells. Histogen’s proprietary, reproducible manufacturing process provides targeted solutions across a broad range of therapeutic indications including hair growth, dermal rejuvenation, joint cartilage regeneration and spinal disk repair.

For more information, please visit www.histogen.com.

Histogen Announces Week 26 HST-001 Study Results for the Treatment of Androgenic Alopecia in Men

Source

Recent Posts

Preclinical Study of Hair Loss Therapeutic Candidate

Preclinical Study of Hair Loss Therapeutic Candidate

/in /by

OliX Pharmaceuticals Announces Results from Preclinical Study of Hair Loss Therapeutic Candidate

OliX Pharmaceuticals, Inc, a leading developer of RNAi therapeutics, announced that it has demonstrated efficacy in a preclinical study of OLX104C, an investigational RNAi therapeutic in development for androgenic alopecia, also known as hair loss.

In the study, OLX104C was administered topically to a mouse model with suppressed hair growth (Dihydrotestosterone, DHT administered mouse). The study evaluated the percentage of hair regrowth and duration of knockdown of the target protein, AR, following a single injection.

Mice receiving OLX104C showed substantial hair regrowth compared to the control group, and results showed that a single dose could inhibit the expression of the target gene for more than three weeks.

“We are advancing a novel and potentially durable approach to treating hair loss with large market potential,” said Dong Ki Lee, PhD, founder and chief executive officer of OliX Pharmaceuticals. “Due to topical administration, our investigational therapy acts directly on the affected area and is rapidly degraded upon exposure to the blood, so it’s free from major systemic side effects such as sexual dysfunction caused by conventional hair loss therapeutics.

Building on our experience evaluating RNAi therapeutics for skin diseases, we plan to initiate clinical trials of OLX104C by 2022.”

According to Inkwood Research, the global hair loss treatment market size is estimated to grow 5.51% annually from $8.4 billion in 2018 to $13.6 billion in 2027.1

Furthermore, OliX has completed patent applications in major global markets, including the United States, Europe, Korea, and Japan, to secure exclusive rights for its hair loss treatment substance.

Dr Lee will discuss the preclinical results of OLX104C and present a corporate overview at SMi’s 12th Annual RNA Therapeutics Virtual Conference on February 11, 2021, at 9:40 a.m. GMT.

About OliX Pharmaceuticals

OliX Pharmaceuticals is a clinical-stage pharmaceutical company developing therapeutics against a variety of disorders by down-regulating expression of disease-causing genes, based on its own proprietary RNAi technology. The Company’s core RNAi platform, asymmetric siRNA (asiRNA), is a unique gene silencing technology based on RNA interference (RNAi), which is considered as the most efficient gene silencing technology.

Based on asiRNA technology, OliX has developed cell penetrating asiRNA (cp-asiRNA), a therapeutic RNAi platform to effectively target locally administrable diseases, such as hypertrophic scar, dry and wet age-related macular degeneration (AMD), subretinal fibrosis, idiopathic pulmonary fibrosis (IPF), and neuropathic pain.

OliX has also developed another therapeutic RNAi platform, GalNAc-asiRNA, to target a variety of liver diseases.

To learn more about the company, visit https://www.olixpharma.com/eng/

1 Inkwood Research. Global Alopecia (Hair Loss) Treatment Market Forecast 2019-2027. Available at: https://www.inkwoodresearch.com/reports/global-alopecia-hair-loss-treatment-market/. Accessed February 9, 2021.

OliX Pharmaceuticals Announces Results from Preclinical Study of Hair Loss Therapeutic Candidate

Source

Recent Posts